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Abstract 24 
Objective 25 
To examine the association between contemporary hormonal contraceptives and endometrial 26 
cancer risk in women younger than age 50.  27 
Study design 28 
Cohort study of women living in Denmark aged 15-49 years through 1995-2014. National registries 29 
provided information about hormonal contraception use, incident endometrial cancer and 30 
confounders.  Ever, current or recent, and former users of any hormonal contraception were 31 
compared with non-users, using Poisson regression to calculate incident rate ratios (RR) with 95% 32 
confidence intervals. Duration, time since last use, tumor-specific and product-specific analyses, and 33 
population prevented fraction, were calculated.    34 
Results 35 
During 21.1 million person-years, 549 incident endometrial cancers occurred, with ever users of any 36 
hormonal contraception having a reduced premenopausal endometrial cancer risk compared with 37 
non-users; RR 0.60 (95% Confidence Interval 0.49 to 0.73).  A lower risk of endometrial cancer was 38 
seen in all current or recent users of any hormonal contraception; 0.65 (0.52-0.83) and combined 39 
contraceptives; 0.57 (0.43 to 0.75), but not progestin-only contraceptives; levonorgestrel 40 
intrauterine system, LNG-IUS; 0.97 (0.66 to 1.42); other progestin-only contraceptives; 0.61 (0.27 to 41 
1.37)].  Increased RRs were found for current use of any hormonal, combined contraceptives or LNG-42 
IUS of ≤ one year, probably because of protopathic bias. Longer durations of use were associated 43 
with significant reductions that became stronger with longer use.  Former users of any hormonal 44 
contraception continued to benefit from a reduced risk of endometrial cancer > 10 years after 45 
stopping.    46 
There was little evidence of differences in risk reduction by the type of progestin in combined oral 47 
contraceptives.  48 
Current or recent use of any hormonal contraception was associated with an approximate halving of 49 
risk of the most common tumor type I carcinoma, and an increased risk of the rarer sarcoma. 50 
Overall the estimated absolute reduced risk of endometrial cancer in ever users of hormonal 51 
contraceptives was 1.4 per 100,000 person-years, or approximately one less endometrial cancer for 52 
every 71,400 women of reproductive age who used hormonal contraception for one year. Use of 53 
hormonal contraception was estimated to prevent 25% of endometrial cancers in this population.  54 
Conclusions  55 
Currently available combined hormonal contraceptives are still associated with enduring protection 56 
against endometrial cancer, particularly for type I carcinomas.  57 
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Implications  62 
We report substantive evidence of the association between different types of contemporary 63 
hormonal contraception and endometrial cancer risk in a national cohort of young Danish women. 64 
Currently available combined hormonal contraceptives are still associated with enduring protection 65 
against endometrial cancer, particularly for type I carcinomas.   66 
1.1 Introduction  67 
In 2018, cancer of the corpus uteri (mostly endometrial) was estimated to be the sixth most frequent 68 
cancer in women globally, accounting for more than 382,000 new cases and 89,929 deaths [1]. Many 69 
countries have seen an increased incidence of endometrial cancer during the last 25 years, possibly 70 
because of rises in the prevalence of obesity, nulliparity and diabetes [2]. However, the absence of 71 
increased incidence in other countries has been attributed to long-lasting protective effects from use 72 
of combined oral contraceptives [2,3].  The Collaborative Group on Epidemiological Studies of 73 
Endometrial Cancer examined the association between oral contraceptive use and risk of 74 
endometrial cancer in an individual participant meta-analysis of 27,276 women with endometrial 75 
cancer and 115,743 controls [3]. The median age at diagnosis was 63 years, and median year of 76 
diagnosis 2001, meaning that most of the oral contraceptive use occurred during the 1960s and 77 
1970s. Hormonal contraception has changed substantially since then, including a lowering of 78 
estrogen dose and introduction of different progestins in combined oral contraceptives.  It is 79 
uncertain whether products used today are still associated with important endometrial cancer 80 
benefits. We report here the first substantive evidence of this relationship for all types of 81 
contemporary hormonal contraception used by a national cohort of women living in Denmark. In 82 
order to examine endometrial cancer risk associated with the hormonal contraceptives currently 83 
used by women of reproductive age, we studied women younger than age 50. 84 
 85 
1.2 Material and methods 86 
The Danish Sex Hormone Register Study [4,5] follows all women aged 15-79 years living in Denmark, 87 
to examine the relationship between hormone use and cardiovascular disease and cancer. Since 88 
1968, each resident in Denmark has had a unique personal identification number in the Civil 89 
Registration System which is used as a unique identifier in all National Registries, enabling the 90 
accurate linkage of their content. The study links data from: the National Register of Medicinal 91 
Product Statistics [for redeemed hormonal contraceptive prescriptions since January 1995]; the 92 
Danish Cancer Registry [for histologically verified cancers since 1943 and family history of 93 
premenopausal (younger than 50 years) breast or ovarian cancer in mothers or sisters]; Statistics 94 
Denmark [for information about educational attainment]; the National Birth Register [for all births 95 
since 1973, smoking status of parous women since 1991 and body mass index (BMI) of parous 96 
women since 2004]; and the National Health Register [for hospital discharge diagnoses and surgeries 97 
since 1977]. 98 
For this paper the eligible study population (n=1,904,094) was all women living in Denmark age 15-99 
49 years during the period January 1995 to December 2014, except women who moved into 100 
Denmark after 1995. We excluded women if they had venous thrombosis, treatment with ovarian 101 
stimulating drugs (Anatomical Therapeutic Chemical Classification code MG03G in the National 102 
Prescription Registry), hysterectomy, bilateral oophorectomy, endometrial hyperplasia or any cancer 103 
(except non-melanoma skin cancer) before study entry. The final population of 1,852,505 women 104 
was followed until: first diagnosis of endometrial cancer (International Classification of Diseases 105 
(ICD), tenth revision [6] code C54); emigration; death; age 50; or end of follow-up (31 December 106 
2014). Women were censored permanently at the date of: diagnosis of another cancer (except non-107 
melanoma skin cancer); venous thrombosis; treatment with ovarian stimulating drugs; bilateral 108 
oophorectomy, hysterectomy or endometrial hyperplasia (which can be a precursor to endometrial 109 
cancer). Women were censored temporarily whilst pregnant and for six months afterwards. 110 
 111 
Information about redeemed prescriptions was updated daily. From this information we designated 112 
the date when: women started (date prescription was redeemed); stopped (date when the 113 
contraception was estimated to finish- based on the number of packs issued for oral contraceptives, 114 
usual length of use for other hormonal contraceptives,  four years for the levonorgestrel intrauterine 115 
system (LNG-IUS) - unless a prescription for a different hormonal contraceptive was redeemed or 116 
pregnancy occurred beforehand); or switched type (date of prescription redemption for a different 117 
product) of hormonal contraceptive). Gaps between prescriptions of less than 28 days were filled in 118 
prospectively [7].   119 
 120 
1.2.1 Statistical analysis 121 
Throughout the follow-up period the hormonal contraceptive status of the women changed 122 
according to when they started, stopped or changed the type of hormonal contraception used. We 123 
categorized and aggregated the endometrial cancers and periods of observation according to the 124 
hormonal contraceptive status of the women throughout the study as: non-user (i.e. no redeemed 125 
prescription for hormonal contraceptives at date of entry to the study and continued not to redeem 126 
a prescription; if a prescription for a hormonal contraceptive was redeemed during the study her 127 
contraceptive status changed to current user on the date of redemption); current or recent (within 128 
one year of stopping) users; or former (more than one year since stopping) users of different 129 
hormonal contraceptives. An ever user had redeemed at least one prescription for hormonal 130 
contraceptive during the study. Once a woman became a user, she could not return to being a non-131 
user.  Women could switch between current or recent and former user categories depending on 132 
their redemption of prescriptions. Our time-varying analyses allowed for these changes. The age 133 
distribution of the entire cohort was used as the standard to calculate age-standardized incidence 134 
rates of endometrial cancer per 100,000 person-years among the different user groups. Endometrial 135 
cancer risk among users of different products was calculated using Poisson regression in SAS version 136 
9.3 (SAS Institute, Inc, Cary, North Carolina) using PROC GENMOD with the distribution set to 137 
Poisson and a log link function. Five-year age bands were used as the time scale in the Poisson 138 
regression. In each model non-users were the reference group and adjusted incidence rate ratios 139 
(RR) with their 95% confidence interval (CI) calculated. Time varying covariate effects were modelled 140 
by adding interactions between the partitioned constant baseline hazard and each pre-specified 141 
covariate. By doing this, we did not assume constant baseline hazard rates over fixed time intervals.  142 
Each model was adjusted such that the risk time was partitioned every time one of these covariates 143 
changed value. The covariates were: hormonal contraceptive use, calendar year, age (15-19, 20-24, 144 
25-29, 30-34, 35-39, 40-44, 45-49 years), educational attainment (elementary school only, high 145 
school only, further education excluding college/university, college/university education, university 146 
education with research qualifications, unknown); parity (0, 1, 2, 3, 4, >4); family history of 147 
premenopausal breast or ovarian cancer (no, yes); tubal sterilization (no, yes) and endometriosis 148 
(no, yes). Among parous women, additional models adjusted for smoking status (current, non-149 
smoker, unknown) and BMI (<18.5, 18.5-25, >25-30, >30, unknown) ascertained at pregnancy. 150 
Smoking status and BMI were not available for other women. 151 
 152 
Our main analysis compared ever, current or recent, and former users of any hormonal 153 
contraception with non-users. Separate analyses examined duration of use (with short-term use 154 
being ≤ one year) and time since last current use, with tests for trend conducted by including the 155 
duration or time since variable as an ordinal variable with values set to the median within each 156 
category [8]. We also stratified our data by tumor histology using the same sets of ICD-O-3 codes[9] 157 
(all ending with behavior invasive digit 3) as the Collaborative Group[3] (Table 1S).   158 
 159 
To minimize any lingering effects from previous use of hormonal contraception, we examined risk 160 
estimates for different products in women followed during the study until their first change of 161 
hormonal contraception. We also calculated risk estimates among women aged 15 years on or after 162 
1st January 1995, for whom complete contraceptive histories were known.  163 
Some women may start or restart hormonal contraception because of symptoms (e.g. heavy 164 
bleeding) from an undiagnosed cancer which is subsequently diagnosed soon afterwards. This could 165 
artificially elevate events in current users of a hormonal contraceptive with a short duration of use. 166 
To explore whether this may have occurred, we undertook two sensitivity analyses on our full cohort 167 
and tumor specific datasets in which we ignored periods of observation for one and two years 168 
before cancer diagnosis date, allocating the event to the hormonal contraceptive group pertaining 169 
one or two years before diagnosis (unless the woman had less than one or two years of observation 170 
before the event in which case she was excluded from the analysis).  171 
 172 
For the full cohort, we calculated the absolute reduction in risk of endometrial cancer in ever users 173 
of hormonal contraceptives. We also calculated the population prevented fraction 174 
(=prevalenceexposure (1-RR)) associated with ever use of any hormonal contraception using the 175 
incidence RR of ever versus non-user of any hormonal contraception.   176 
 177 
1.2.2 Ethics approval 178 
Even though ethical approval is not required for register-based studies in Denmark, approval for the 179 
research was obtained from the Danish Data Protection Agency and Health Data Board. The data 180 
were held, with personal identification number codes encrypted, and analyzed within the secure 181 
data repository at Statistics Denmark. In accordance with the regulations of Statistics Denmark 182 
around statistical disclosure, outcomes where <3 endometrial cancers occurred are presented as <3, 183 
the corresponding total person-years is rounded to the nearest 5 and the RR (95% CI) is not shown. 184 
 185 
1.3 Results 186 
There were 362 incident endometrial cancers among non-users of hormonal contraceptives and 187 187 
in ever users, during 21.1 million person-years of observation.  Combined oral contraceptives 188 
containing gestodene, desogestrel or levonorgestrel accounted for almost two-thirds of all hormonal 189 
contraception use among current or recent users (Table 1). The LNG-IUS was the most commonly 190 
used non-oral hormonal contraceptive and was more frequently used among parous than 191 
nulliparous women. In the full cohort, women who had ever used any hormonal contraception had a 192 
reduced incidence rate of endometrial cancer in comparison to non-users; RR 0.60 (0.49 to 0.73) 193 
(Table 2). A similarly reduced RR of endometrial cancer was also observed among current or recent 194 
users of any hormonal contraception; RR 0.65 (0.52 to 0.83) and combined contraceptives; RR 0.57 195 
(0.43 to 0.75), but not progestin-only contraceptives; LNG-IUS RR 0.97 (0.66 to 1.42); all other 196 
progestin-only products RR 0.61 (0.24 to 1.37). An increased RR was observed with one year or less 197 
of current use of any hormonal contraception, combined oral contraceptives or LNG-IUS (Table 2).  198 
Users of these products for longer durations had a reduced RR of endometrial cancer, an effect that 199 
strengthened with increasing duration of use. In former users of any hormonal contraception, there 200 
remained a reduced RR of endometrial cancer more than 10 years after stopping; RR 0.57 (0.36 to 201 
0.89). When the data for former users were stratified by duration of previous use and time since last 202 
use, the protective effect of hormonal contraception was stronger with longer durations of use 203 
irrespective of time since stopping (Table 3). 204 
 205 
The subset of women who were followed until their first switch in hormonal contraception, together 206 
with non-users, accounted for 71% (15,057,542/21,161,314 person-years) of all periods of 207 
observation in the cohort (Table 4). In this subset, ever, former and current or recent users of any 208 
hormonal contraceptives all had a more than a 30% reduced RR of endometrial cancer compared 209 
with non-users.  An increased RR of endometrial cancer was observed again among those with less 210 
than one year of any hormonal contraception or the LNG-IUS. Longer durations of use of any 211 
hormonal or of combined contraceptives were associated with a reduced RR. The reduced RR of 212 
endometrial cancer in former users persisted at least 10 years after ceasing hormonal contraception. 213 
Current or recent users of combined hormonal contraceptives had a reduced RR of endometrial 214 
cancer; RR 0.41 (0.27 to 0.62), with a reduction seen among current or recent users of the most 215 
frequently used combined oral contraceptive containing gestodene.  Although based on limited data, 216 
current or recent use of other progestin-only products (i.e. excluding the LNG-IUS) was not 217 
associated with endometrial cancer; RR 0.73 (0.23 to 2.27). Most cancers in LNG-IUS users (12/21) 218 
occurred within the first year of use; the median time between prescription redemption and cancer 219 
diagnosis was 281 days (interquartile range 41-698). Thus, the increased RR in LNG-IUS users overall 220 
was due to a high rate of endometrial cancers among users during the first year of use. 221 
 222 
The pattern of risk estimates for the different products when the full cohort was examined was 223 
broadly similar to that in women followed until first switch, except for current or recent use of the 224 
LNG-IUS which was no longer associated with an increased RR of endometrial cancer (Table 2S). 225 
Similar risk estimates were found in the full cohort among parous women after adjustment for 226 
smoking and BMI (Table 3S) and after similar adjustments among those parous women followed 227 
until their first switch of hormonal contraception (data not shown). Only six endometrial cancers 228 
occurred during 5.4 million person-years among women with a complete contraceptive history, 229 
precluding calculation of incidence RRs in this subset of the cohort. 230 
 231 
Type I carcinomas accounted for 68% (373/549) of all endometrial cancers in the full cohort (Table 232 
5). Both current or recent use of any hormonal contraception, combined contraception and former 233 
use had an approximate halving of RRs for type I carcinoma. Current or recent use of any hormonal 234 
contraception was associated with an increased RR of sarcoma; RR 1.82 (1.11 to 3.02), a relationship 235 
not seen in former users. When examined by type of hormonal contraception, there was an 236 
increased RR of sarcoma among current or recent users of LNG-IUS; RR 3.24 (1.43 to 7.34) but not 237 
combined products; RR 1.60 (0.90 to 2.84).  238 
 239 
The sensitivity analysis which excluded from the full cohort dataset periods of observation one year 240 
before diagnosis, resulted in similar patterns overall albeit with smaller RRs (Table 2 & Table 4S).  In 241 
this analysis, current use of hormonal contraceptives of any type for short durations was no longer 242 
associated with an increased RR of endometrial cancer. A similar pattern was seen when two years 243 
of observation was excluded, although the risk estimates were more imprecise (data not shown). In 244 
a sensitivity analysis of the tumor specific dataset, exclusion of one year’s period of observation 245 
resulted in overall smaller RRs and the loss of statistical significance for the risk estimates for 246 
sarcoma among current or recent users of any hormonal contraception or the LNG-IUS (Table 5S). 247 
Similar results were again seen when two years of observation prior to the diagnosis of endometrial 248 
cancer were excluded from the analysis (data not shown). 249 
 250 
Overall the estimated absolute reduced risk of endometrial cancer in ever users of hormonal 251 
contraceptives was 1.4 per 100,000 person-years, or approximately one less endometrial cancer for 252 
every 71,400 women of reproductive age who used hormonal contraception for one year. The 253 
population prevented fraction was estimated to be 25% i.e. use of hormonal contraception 254 
prevented 25% of endometrial cancers in the study population.  255 
 256 
1.4 Discussion  257 
In this cohort study of women of reproductive age in Denmark, current or recent use of any 258 
hormonal contraception and of combined contraceptives was associated with a reduced risk of 259 
endometrial cancer. For combined contraceptives, there was little evidence of differences in risk 260 
reduction according to their progestin content. Reductions became stronger with longer duration of 261 
use and persisted among former users. It is unclear whether progestin-only contraceptives have the 262 
same benefits. 263 
Strengths of our study include more than 1.8 million women studied, 21.1 million person-years of 264 
observation and the examination of all types of hormonal contraception in use between 1995 and 265 
2014. Recall bias about contraceptive use was avoided by the prospective collection of information 266 
about redeemed prescriptions. We were able to adjust for several possible confounders, although 267 
information about smoking habits and BMI was available only for parous women for part of the 268 
study period. These adjustments did not materially change the risk estimates.  It is possible, 269 
however, that residual confounding influenced our findings. An unknown proportion of women 270 
deemed to be non-users will have been previous users of hormonal contraceptives who stopped 271 
before our study began in January 1995. The effect of this misclassification of hormonal 272 
contraceptive status will be to move the RRs towards the null, thus underestimating the ‘real’ effects 273 
of hormonal contraceptives.  274 
 275 
Risk estimates attributed to a particular product might reflect persisting effects from previous use of 276 
another contraceptive(s). We tried to minimize such effects by examining associations for different 277 
products among women followed until their first switch of hormonal contraception in the study, 278 
even though this approach meant that fewer cases of endometrial cancer among less popular 279 
preparations. Nevertheless, there was no evidence of important differences between combined 280 
contraceptives containing different progestins. Although it is likely that that protopathic bias 281 
occurred in short-tern users overall, there is less reason to suspect that this operated differently 282 
within the preparations containing different progestins. We were unable to calculate risk estimates 283 
in women for whom their full contraceptive history was known i.e. the subset of women who were 284 
15 years on or after 1st January 1995, because of the low incidence of endometrial cancer in young 285 
women.  286 
 287 
The Collaborative Group’s reanalysis of 36 studies of oral contraceptives and endometrial cancer 288 
found an overall relative risk between ever and never users of 0.69 (0.67 to 0.72). We found a 289 
slightly stronger overall reduced risk among ever users of any hormonal contraception; RR 0.60 (0.49 290 
to 0.73), possibly because our ever user group included a larger proportion of current or recent users 291 
than women included in the Collaborative Group re-analysis. The Collaborative Group found a 292 
reduced risk of type I (typically considered to be estrogen-dependent) and II (estrogen-independent) 293 
carcinoma but not sarcoma. We also found a reduced risk of type I tumors. The Collaborative Group 294 
estimated that in 21 countries during 1965-2014 combined oral contraceptive use had prevented 295 
400,000 endometrial cancers in women aged 30-74. In our study of younger women, the estimated 296 
population prevented fraction was 25%, suggesting continuing substantial endometrial cancer 297 
benefits from contemporary hormonal contraceptives- particularly combined products. 298 
 299 
Few studies have examined the LNG-IUS in relation to endometrial cancer risk [10-12]. The 300 
Endometrial Cancer Consortium combined data from four cohort and 14 case-control studies to 301 
examine the endometrial cancer risk associated with type of intrauterine device [10]. Hormone-302 
releasing devices did not appear to alter the risk although few women in the analysis had used these 303 
products (adjusted odds ratio 0.97, 95% CI 0.44 to 2.14). Soini et al followed 93,843 women who had 304 
used the LNG-IUS for menorrhagia treatment [11]. During more than 850,000 person-years of 305 
observation, users had a reduced risk of any type of corpus uteri cancer; standardized incidence 306 
ratio, SIR 0.59 (95% CI 0.45 to 0.77) and endometrial adenocarcinoma; SIR 0.46 (0.33 to 0.64), with 307 
evidence of more protection with increased duration of use.  This study, however, could not adjust 308 
for previous use of oral contraceptives, which are associated with long-lasting protective effects on 309 
the endometrium [3,13]. The study did not find a reduced risk of uterine sarcoma; SIR 1.44 (0.86 to 310 
2.28) [11].  We were also unable to find in either our main or sensitivity analyses a protective effect 311 
for sarcoma from hormonal contraception generally, and the LNG-IUS specifically.  312 
 313 
A cohort study of 104,318 women enrolled in the Norwegian Women and Cancer Study also 314 
reported a reduced risk of endometrial cancer among ever users of the LNG-IUS; RR 0.22 (0.13 to 315 
0.40) [12]. The study adjusted for several possible confounders including ever use of oral 316 
contraceptives but (unlike our study) almost 50% of the ever users of LNG-IUS in the cohort were 317 
peri- or post-menopausal. Our results do not confirm a protective effect associated with the LNG-IUS 318 
among premenopausal women. Indeed, among the subset followed until first switch, we found an 319 
increased risk of endometrial cancer in current or recent users of the LNG-IUS, mostly because of an 320 
increased risk during the first year of use. We did not have the reason why women redeemed a 321 
prescription for a hormonal contraceptive in our study. As well as for contraception, hormonal 322 
contraceptives can be used to treat menstrual irregularities such as heavy bleeding, including 323 
bleeding symptoms arising from pre-cancerous conditions such as endometrial hyperplasia. We 324 
censored women at the date of diagnosis of endometrial hyperplasia. It is possible, however, that 325 
some women experienced menstrual irregularities and began using hormonal contraception 326 
specifically for this problem, which subsequently did not resolve and which after further 327 
investigation was found to be due to an undiagnosed endometrial cancer. The effect of such a 328 
protopathic bias would be to produce a higher risk of cancer early in the period of contraceptive use. 329 
Our sensitivity analyses in which we excluded periods of observation prior to diagnosis, and which 330 
no longer found an increased risk of endometrial cancer among current users of hormonal 331 
contraceptives with short durations of use, suggest that protopathic bias has affected our results. 332 
The overall effect will be to underestimate in ever users the ‘true’ protective effect of hormonal 333 
contraception on endometrial cancer risk. In other words, the overall estimates of endometrial 334 
cancer in ever users of hormonal contraceptives seen in our study are likely to be conservative. This 335 
bias may also explain our finding of an increased risk of sarcoma in association with current or recent 336 
use of progestin-only products.  337 
 338 
Although the sensitivity analyses have addressed concerns about possible protopathic bias, they do 339 
not remove any lingering effects from previous use of combined hormonal contraceptives. It is 340 
possible that the significantly reduced risk of any endometrial cancer among current or recent users 341 
of the LNG-IUS (Table 4S), and type I endometrial cancer (Table 5S) results from previous combined 342 
hormonal contraceptive use rather than the LNG-IUS itself. Unfortunately, very few women in our 343 
study (i.e. <1% of ever hormonal contraceptive users for which we have full contractive history 344 
documented, data not shown) were exclusive users of progestin-only products, preventing a direct 345 
examination of the cancer risks associated with these products.  We advise caution, therefore, when 346 
interpreting the progestin-only risk estimates. 347 
 348 
1.4.1 Conclusion 349 
Users of more recently available combined hormonal contraceptives continue to benefit from a 350 
substantial, persisting reduced risk of endometrial cancer. This appears to be a class rather than 351 
product-specific effect.  352 
 353 
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Table 1. Characteristics of non, former and current or recent users of different types of hormonal contraception. 
Type of hormonal 
contraception used 









































  7,935,787 35.1 (11.9) 21.8 5.2 86.1 6.6 0.3 2.3 24.4 (5.2) 21.4 
Former use (>12 months ago) 4,405,210 36.6 (8.0) 18.2 7.6 46.2 9.5 0.9 2.8 24.0 (4.8) 24.3 
Current or recent use 8,820,317 29.2 (8.5) 13.8 5.1 74.8 1.1 0.5 2.5 24.1 (4.9) 24.7 
Current or recent use of combined hormonal contraception: 
     Oral 50 µg EE** 
 
          
     Norethisterone 1995-2002 57,339 32.2 (8.8) 32.6 2.0 89.4 2.7 0.4 2.6 24.7 (5.3) 46.6 
     Levonorgestrel 1995-2009 82,384 34.6 (9.5) 31.3 3.4 86.5 3.3 0.9 2.5 24.7 (5.4) 46.0 
     Oral 20-40 µg EE           
     Norethisterone 1995- 164,966 28.1 (7.9) 21.8 3.9 86.6 1.0 0.2 2.8 25.0 (5.3) 32.0 
     Levonorgestrel 1995- 1,014,902 30.5 (8.9) 15.0 3.3 77.1 0.9 0.4 2.3 24.2 (4.9) 27.5 
     Norgestimate 1995- 720,084 27.9 (8.0) 14.5 4.9 78.3 0.9 0.5 2.4 24.3 (5.0) 27.8 
     Desogestrel 1995- 1,657,589 27.6 (8.1) 13.1 4.9 79.8 0.7 0.6 2.4 24.3 (4.9) 26.1 
     Gestodene 1995- 2,983,440 27.7 (8.0) 13.8 4.7 79.7 0.7 0.4 2.5 24.4 (5.0) 26.5 
     Drospirenone 2001- 591,917 26.6 (7.9) 8.9 5.1 78.4 0.7 0.8 2.3 23.9 (4.7) 24.1 
     Cyproterone 1995- 317,600 27.3 (7.4) 11.6 6.4 85.3 0.7 0.4 2.4 23.5 (4.7) 28.0 
     E2V
††
, dienogest       2009- 13,990 33.8 (10.2) 8.7 6.9 55.4 2.5 1.7 2.3 23.5 (4.3) 19.0 
     Non-oral  
 
          
     Patch  2003- 15,347 27.0 (7.8) 14.1 2.1 63.6 0.9 0.9 1.7 23.5 (4.7) 28.3 
     Vaginal ring  2002- 124,212 28.2 (7.1) 8.6 5.6 68.7 0.5 0.7 2.2 23.7 (4.5) 24.0 
Current or recent use of progestin-only products: 
     Oral 
 
        
  
      
     Norethisterone 1995- 157,796 34.8 (8.3) 17.5 7.2 57.7 1.0 0.5 2.8 23.6 (4.6) 20.0 
     Levonorgestrel 1995-2005 11,513 37.6 (8.1) 22.1 7.9 80.0 1.1 0.2 2.9 24.1 (4.4) 18.2 
     Desogestrel 2001- 123,209 32.4 (8.3) 10.6 7.1 45.1 1.1 1.6 3.0 23.7 (4.6) 18.4 
     Non-oral            
     MPA depot 1995- 27,783 27.7 (9.0) 36.8 0.4 72.5 2.2 0.6 2.4 25.7 (6.3) 54.5 
     Implant 1999- 58,269 26.9 (8.5) 18.0 1.8 68.4 1.6 0.5 2.1 25.0 (5.7) 35.3 
     LNG-IUS 1995- 697,977 39.9 (6.5) 12.3 9.6 33.1 4.0 1.1 2.9 23.9 (4.5) 18.6 
*From this year onwards to end of the study. †Percentage with elementary school only education and percentage with University with research qualification education. ‡Family history of premenopausal breast or 
ovarian cancer. §Available since 2004 only in parous women n=322,619, 73% unknown BMI. ǁAvailable since 1991 only in parous women n=512,075, 57% unknown smoking. ¶No record of redeemed prescriptions for 
hormonal contraceptives during study period. **Ethinylestradiol. ††Estradiol valerate. Descriptive statistics were calculated as the average person-time with a given characteristic divided by the total amount of 
person-time on a specific hormonal contraception. The descriptive percentages represent the percentage of person-time with a given characteristic.
Table 2. Incidence rate ratio of endometrial cancer in users of hormonal contraception (full cohort) 




Adjusted* rate ratio 
(95% confidence 
interval) 
Non-use 7,935,787 362 3.3 1.00 
Ever use (any hormonal) 13,225,527 187 1.9 0.60 (0.49 to 0.73) 
Former use (any hormonal) 4,405,210 87 1.7 0.54 (0.42 to 0.70) 
Current or recent use:     
Any hormonal 8,820,317 100 2.1 0.65 (0.52 to 0.83) 
Combined 7,743,769 62 1.8 0.57 (0.43 to 0.75) 
LNG-IUS 697,977 32 2.7 0.97 (0.66 to 1.42) 
Other progestin-only 378,571 6 2.2 0.61 (0.27 to 1.37) 
     
Duration of current use (any hormonal contraception)†   
≤1 year 1,262,134 38 7.6 2.48 (1.76 to 3.50) 
>1-≤5 years 4,054,649 38 2.4 0.70 (0.50 to 0.98) 
>5-≤10 years 2,575,287 14 0.9 0.28 (0.16 to 0.48) 
>10 years 928,248 10 0.9 0.22 (0.12 to 0.42) 
     
Duration of current use (combined)‡     
≤1 year 1,183,171 25 6.2 1.95 (1.29 to 2.96) 
>1-≤5 years 3,640,510 20 1.8 0.56 (0.35 to 0.90) 
>5-≤10 years 2,201,667 11 1.0 0.32 (0.17 to 0.58) 
>10 years 718,422 6 0.7 0.18 (0.08 to 0.41) 
     
Duration of current (LNG-IUS) §    
≤1 year 23,511 12 26.6 7.97 (4.47 to 14.20) 
>1-≤5 years 259,471 15 2.9 0.95 (0.56 to 1.61) 
>5 years 414,995 5 0.9 0.24 (0.10 to 0.60) 
    
Time since last current use of any hormonal contraception¶   
>1-≤5 years 2,412,035 36 1.7 0.56 (0.40 to 0.80) 
>5-≤10 years 1,357,368 28 1.5 0.51 (0.34 to 0.76) 
>10 years 635,807 23 1.6 0.57 (0.36 to 0.89) 
     
Sensitivity analysis: incidence rate ratio of endometrial cancer in users of hormonal contraception with one year 
period of exposure prior to diagnosis removed (see Table 4S for full results of sensitivity analysis) 
Non-use 7,935,261 356  1.00* 
Current or recent use:     
Any hormonal 8,820,055 67  0.41 (0.31 to 0.55) 
Combined 7,743,561 42  0.35 (0.25 to 0.48) 
LNG-IUS 697,937 18  0.58 (0.36 to 0.95) 
Other progestin-only 378,558 7  0.71 (0.33 to 1.51) 
*Adjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal 
sterilization and endometriosis. 
† p-trend <0.001; ‡ p-trend <0.001; § p-trend <0.001; ¶ p-trend <0.001  
 
Table 3. Incidence rate ratio of endometrial cancer in former users of hormonal contraception by duration of use and time since last use (full cohort). 
 
 Time since last use 
 >1-≤5 years >5-≤10 years >10 years 
Duration of use Person-years Events RR (95% CI)* Person-years Events RR (95% CI)* Person-years Events RR (95% CI)* 
≤1 year 658,343 16 0.84 (0.51 to 1.40) 455,697 12 0.62 (0.34 to 1.11) 302,238 14 0.63 (0.36 to 1.10) 
>1-≤5 years 1,028,001 14 0.59 (0.34 to 1.02) 619,453 12 0.51 (0.28 to 0.92) 295,454 9 0.43 (0.22 to 0.87) 
>5 years 725,692 6 0.24 (0.10 to 0.54) 282,218 4 0.26 (0.09 to 0.70) 38,110 <3† n/a 
*Adjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal sterilization and endometriosis. 
†Data not available for presentation due to less than three events, estimates therefore not available (n/a) and total person-years rounded to nearest five. 
 
 
Table 4. Incidence rate ratio of endometrial cancer in users of different types of hormonal 1 
contraception in women followed up until first switch in hormonal contraception i.e. “no change 2 
cohort”. 3 
 Person-years Endometrial cancer, N Adjusted* rate ratio (95% confidence interval) 
Non-use 7,935,787 362 1.00 
Ever use (any hormonal) 7,121,755 111 0.61 (0.49 to 0.76) 
Former use (any hormonal) 2,536,713 62 0.59 (0.44 to 0.78) 
Current or recent use:    
 Any hormonal 4,585,042 49 0.63 (0.47 to 0.86) 
Combined 4,312,942 25 0.41 (0.27 to 0.62) 
LNG-IUS 168,442 21 1.65 (1.05 to 2.59) 
Other progestin-only 103,658 3 0.73 (0.23 to 2.27) 
Current or recent use of combined hormonal contraception: 
Oral     
Norethisterone 50 µg EE 36,400 <3†
 
n/a 
Levonorgestrel 50 µg EE 47,140 <3 n/a 
Norethisterone 30-35 µg EE 115,940 <3 n/a 
Levonorgestrel 30-35 µg EE 518,530 <3 n/a 
Desogestrel 20-30 µg EE 988,159 5 0.43 (0.18 to 1.04) 
Gestodene 20-35 µg EE 1,885,631 6 0.27 (0.12 to 0.60) 
Drospirenone 20-35 µg EE 188,800 <3 n/a 
Norgestimate 35 µg EE 375,374 7 1.61 (0.76 to 3.43) 
Cyproterone 30 µg EE 141,980 <3 n/a 
Estradiol valerate, dienogest 1,010 <3 n/a 
Non-oral    
Patch  2,250 <3 n/a 
Vaginal ring 11,730 <3 n/a 
Current or recent use of progestin-only contraception: 
Oral     
Norethisterone 66,760 <3 n/a 
Levonorgestrel  6,950 <3 n/a 
Desogestrel 12,100 <3 n/a 
Non-oral    
MPA depot 7,300 <3 n/a 
Implant 10,550 <3 n/a 
Duration of current use (any hormonal contraception)  
≤1 year 1,059,203 28 2.18 (1.46 to 3.23) 
>1-≤5 years 2,309,005 15 0.46 (0.28 to 0.78) 
>5-≤10 years 960,090 <3 n/a 
>10 years 256,742 5 0.35 (0.14 to 0.85) 
Duration of current use (combined)   
≤1 year 1,000,323 16 1.46 (0.87 to 2.45) 
>1-≤5 years 2,143,641 4 0.18 (0.07 to 0.49) 
>5-≤10 years 919,150 <3 n/a 
>10 years 249,829 4 0.30 (0.11 to 0.82) 
Duration of current use (LNG-IUS)   
≤1 year 19,340 12 9.39 (5.27 to 16.70) 
>1-≤5 years 118,170 8 0.90 (0.45 to 1.83) 
>5 years 30,935 <3 n/a 
Time since last current use of any hormonal contraception  
>1-≤5 years 1,266,623 23 0.65 (0.42 to 0.99) 
>5-≤10 years 806,785 18 0.51 (0.32 to 0.83) 
>10 years 463,305 21 0.60 (0.38 to 0.96) 
*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal sterilization and 4 
endometriosis.
 
†Data not available for presentation due to less than three events, estimates therefore not available (n/a) 5 
and total person-years rounded to nearest five. 6 
  7 
Table 5. Incidence rate ratio of different histological types of endometrial cancer associated with 8 
hormonal contraception (full cohort). 9 
 Person-years Endometrial cancer, N Adjusted* rate ratio  
(95% confidence interval) 
Type I    
Non-use 7,935,787 264 1.00 
Current or recent use:    
Any hormonal contraception 8,820,317 52 0.47 (0.35 to 0.65) 
Combined 7,743,770 32 0.42 (0.28 to 0.61) 
LNG-IUS 697,980 17 0.68 (0.41 to 1.13) 
Other progestin-only 378,570 3 0.41 (0.13 to 1.29) 
Former use 4,405,210 57 0.47 (0.34 to 0.64) 
    
Type II    
Non-use 7,935,787 22 1.00 
Current or recent use:    
Any hormonal contraception 8,820,317 7 0.73 (0.28 to 1.86) 
Combined 7,7,43,770 <3† n/a 
LNG-IUS 697,980 5 2.99 (0.97 to 9.23) 
Other progestin-only 378,570 <3 n/a 
Former use 4,405,210 5 0.56 (0.19 to 1.65) 
    
Sarcomas     
Non-use 7,935,787 47 1.00 
Current or recent use:    
Any hormonal contraception 8,820,317 27 1.82 (1.11 to 3.02) 
      Combined 7,743,770 18 1.60 (0.90 to 2.84) 
      LNG-IUS 697,980 8 3.24 (1.43 to 7.34) 
      Other progestin-only 378,570 <3 n/a 
Former use 4,405,210 13 1.05 (0.53 to 2.05) 
    
Malignant tumor not otherwise specified   
Non-use 7,935,787 29 1.00 
Current or recent use:    
Any hormonal contraception 8,820,317 14 0.65 (0.32 to 1.30) 
      Combined 7,743,770 11 0.69 (0.32 to 1.48) 
      LNG-IUS 697,980 <3 n/a 
      Other progestin-only 378,570 <3 n/a 
Former use 4,405,210 12 0.56 (0.27 to 1.16) 
*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal 10 
sterilization and endometriosis. †Data not available for presentation due to less than three events, 11 
estimates therefore not available (n/a) and total person-years rounded to nearest five. 12 
  13 
Table 1S. ICD-O-3 codes used to classify histological types of endometrial cancer. 14 
Histological type ICD-O-3 (9) codes (all ending with behavior invasive digit 3) 
Type I M8380/8381/8382/8383/8210/8211/8260/8262/8263/8570/8480/8481/8140 
  





Malignant tumor not All other morphology codes supplied with the C54 cancer registration 
otherwise specified  
   15 
Table 2S. Incidence rate ratio of endometrial cancer in users of different hormonal contraceptive 16 
products during follow-up of the full cohort. 17 
 Person-years Endometrial 
cancer, N 
Adjusted* rate ratio (95% 
confidence interval) 
Non-use 7,935,787 362 1.00 
    
Current or recent use of combined hormonal contraception: 
Oral     
Norethisterone 50 µg EE 57,340 <3† n/a 
Levonorgestrel 50 µg EE 82,234 3 0.94 (0.30 to 2.92) 
Norethisterone 30-35 µg EE 164,966 4 1.71 (0.63 to 4.59) 
Levonorgestrel 30-35 µg EE 1,014,902 8 0.36 (0.18 to 0.73) 
Desogestrel 20-30 µg EE 1,657,589 10 0.47 (0.25 to 0.88) 
Gestodene 20-35 µg EE 2,983,440 18 0.47 (0.29 to 0.77) 
Drospirenone 20-35 µg EE 591,917 8 1.32 (0.64 to 2.70) 
Norgestimate 35 µg EE 720,084 10 1.07 (0.56 to 2.02) 
Cyproterone 30 µg EE 317,600 <3 n/a 
Estradiol valerate, dienogest 13,990 <3 n/a 
Non-oral    
Patch  15,350 <3 n/a 
Vaginal ring 124,210 <3 n/a 
Current or recent use of progestin-only contraception: 
Oral     
Norethisterone 157,796 3 0.59 (0.19 to 1.83) 
Levonorgestrel  11,510 <3 n/a 
Desogestrel 123,210 <3 n/a 
Non-oral    
MPA depot 27,780 <3 n/a 
Implant 58,270 <3 n/a 
LNG-IUS 697,977 32 0.95 (0.65 to 1.40) 
*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal 18 
sterilization and endometriosis. †Data not available for presentation due to less than three events, 19 
estimates therefore not available (n/a) and total person-years rounded to nearest five. 20 
 21 
  22 
Table 3S. Incidence rate ratio of endometrial cancer in users of different hormonal contraceptive 23 
products in follow-up of the full cohort: all parous women. 24 
 Person-years Endometrial 
cancer, N 
Adjusted* rate ratio  
(95% confidence interval) 
Non-use 5,501,750 216 1.00 
Ever use (any hormonal) 9,934,478 130 0.66 (0.52 to 0.85) 
Former use (any hormonal) 3,716,323 57 0.54 (0.39 to 0.74) 
Current or recent use:    
 Any hormonal 6,218,155 73 0.78 (0.59 to 1.04) 
Combined 5,282,426 40 0.65 (0.46 to 0.92) 
LNG-IUS 657,424 27 1.08 (0.70 to 1.66) 
Other progestin-only 278,304 6 1.02 (0.45 to 2.32) 
    
Current or recent use of combined hormonal contraception: 
Oral     
Norethisterone 50 µg EE 48,760 <3† n/a 
Levonorgestrel 50 µg EE 67,310 <3 n/a 
Norethisterone 30-35 µg EE 138,811 3 2.23 (0.71 to 7.01) 
Levonorgestrel 30-35 µg EE 623,426 4 0.31 (0.11 to 0.84) 
Desogestrel 20-30 µg EE 1,135,914 6 0.51 (0.22 to 1.15) 
Gestodene 20-35 µg EE 2,106,407 12 0.56 (0.31 to 1.01) 
Drospirenone 20-35 µg EE 337,856 6 1.87 (0.82 to 4.29) 
Norgestimate 35 µg EE 536,313 7 1.31 (0.61 to 2.79) 
Cyproterone 30 µg EE 196,890 <3 n/a 
Estradiol valerate, dienogest 8,235 <3 n/a 
Non-oral    
Patch  9,260 <3 n/a 
Vaginal ring 73,240 <3 n/a 
Current or recent use of progestin-only contraception: 
Oral     
Norethisterone 134,453 3 0.91 (0.29 to 2.86) 
Levonorgestrel  9,950 <3 n/a 
Desogestrel 88,960 <3 n/a 
Non-oral    
MPA depot 13,920 <3 n/a 
Implant 31,020 <3 n/a 
    
Duration of current use of any hormonal contraception  
≤1 year 850,560 27 2.95 (1.96 to 4.45) 
>1-≤5 years 2,753,004 28 0.84 (0.56 to 1.26) 
>5-≤10 years 1,907,157 10 0.32 (0.17 to 0.60) 
>10 years 707,433 8 0.30 (0.14 to 0.62) 
    
Time since last current use of any hormonal contraception  
>1-≤5 years 1,990,299 29 0.71 (0.48 to 1.06) 
>5-≤10 years 1,168,143 14 0.38 (0.22 to 0.66) 
>10 years 557,881 14 0.49 (0.27 to 0.87) 
*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal sterilization, 25 
endometriosis, antenatal smoking status and body mass index.
 †
Data not available for presentation due to less than three 26 
events, estimates therefore not available (n/a) and total person-years rounded to nearest five. 27 
Table 4S. Sensitivity analysis: incidence rate ratio of endometrial cancer in users of hormonal 28 
contraception with one year period of exposure prior to diagnosis removed (full cohort). 29 
 Person-years Endometrial 
cancer, N 
Adjusted* rate ratio 
(95% confidence 
interval) 
Non-use 7,935,261 356 1.00 
Ever use (any hormonal) 13,225,087 159 0.50 (0.40 to 0.61) 
Former use (any hormonal) 4,405,032 92 0.59 (0.46 to 0.76) 
Current or recent use:    
Any hormonal 8,820,055 67 0.41 (0.31 to 0.55) 
Combined 7,743,561 42 0.35 (0.25 to 0.48) 
LNG-IUS 697,937 18 0.58 (0.36 to 0.95) 
Other progestin-only 378,558 7 0.71 (0.33 to 1.51) 
    
Duration of current use (any hormonal contraception)†  
≤1 year 1,262,087 13 0.75 (0.43 to 1.31)  
>1-≤5 years 4,054,530  32 0.55 (0.38 to 0.80)  
>5-≤10 years 2,575,220  14 0.27 (0.16 to 0.47)  
>10 years 928,219  8 0.20 (0.10 to 0.42)  
    
Duration of current use (combined)‡    
≤1 year 1,183,131 9  0.61 (0.31 to 1.19) 
>1-≤5 years 3,640,418 18  0.45 (0.27 to 0.73) 
>5-≤10 years  2,201,611 10  0.26 (0.14 to 0.49) 
>10 years 718,401 5  0.17 (0.07 to 0.41) 
    
Duration of current (LNG-IUS) §   
≤1 year 23,505 <3 n/a 
>1-≤5 years 259,451 10 0.69 (0.37 to 1.31) 
>5 years 414,980 6 0.36 (0.16 to 0.82) 
    
   
Time since last current use of any hormonal contraception¶  
>1-≤5 years 2,411,948 41 0.63 (0.45 to 0.88) 
>5-≤10 years 1,357,312 30 0.55 (0.37 to 0.80) 
>10 years 635,772 21 0.59 (0.37 to 0.94) 
*Adjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal 30 
sterilization and endometriosis. 31 
† p-trend <0.001; ‡ p-trend <0.001; § p-trend <0.001; ¶ p-trend <0.001  32 
  33 
Table 5S. Sensitivity analysis: incidence rate ratio of different histological types of endometrial 34 
cancer associated with hormonal contraception with one year period of exposure prior to diagnosis 35 
removed (full cohort). 36 
 Person-years Endometrial cancer, N Adjusted* rate ratio  
(95% confidence interval) 
Type I    
Non-use 7,935,261 259 1.00 
Current or recent use:    
Any hormonal contraception 8,820,055 31 0.26 (0.18 to 0.39) 
Combined 7,743,560 20 0.23 (0.14 to 0.37) 
LNG-IUS 697,937 7 0.30 (0.14 to 0.64) 
Other progestin-only 378,560 4 0.55 (0.20 to 1.47) 
Former use 4,405,032 60 0.50 (0.37 to 0.68) 
    
Type II    
Non-use 7,935,261 23 1.00 
Current or recent use:    
Any hormonal contraception 8,820,055 4 0.39 (0.13 to 1.24) 
Combined 7,7,43,560 <3† n/a 
LNG-IUS 697,937 3 1.98 (0.52 to 7.53) 
Other progestin-only 378,560 <3 n/a 
Former use 4,405,032 6 0.73 (0.26 to 2.02) 
    
Sarcomas     
Non-use 7,935,261 45 1.00 
Current or recent use:    
Any hormonal contraception 8,820,055 19 1.25 (0.71 to 2.22) 
      Combined 7,743,560 13 1.11 (0.58 to 2.12) 
      LNG-IUS 697,937 5 2.15 (0.80 to 5.78) 
      Other progestin-only 378,560 <3 n/a 
Former use 4,405,032 14 1.20 (0.61 to 2.34) 
    
Malignant tumor not otherwise specified   
Non-use 7,935,261 29 1.00 
Current or recent use:    
Any hormonal contraception 8,820,055 13 0.64 (0.31 to 1.30) 
      Combined 7,743,560 9 0.57 (0.25 to 1.30) 
      LNG-IUS 697,937 3 0.80 (0.23 to 2.77) 
      Other progestin-only 378,560 <3 n/a 
Former use 4,405,032 12 0.62 (0.30 to 1.30) 
*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal 37 
sterilization and endometriosis. †Data not available for presentation due to less than three events, 38 
estimates therefore not available (n/a) and total person-years rounded to nearest five. 39 
 40 
 41 
